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The influenza A virus H1N1 and H3N2 components of the live, attenuated 
influenza vaccine (LAIV) encodes HA and NA gene segments from circulating virus 
strains with the remaining gene segments derived from the cold-adapted master donor 
virus, A/Ann Arbor/6/1960 (H2N2). In addition to the temperature sensitivity mutations 
mapped to PB1, PB2, and NP, some studies demonstrate that the M segment can 
contribute to LAIV attenuation through an Ala to Ser mutation at M2 position 86 
acquired during cold adaptation of A/Ann Arbor/6/1960; a mutation that is not found in 
any other influenza A virus strain. To test the hypothesis that the M2-S86A mutation 
contributes to LAIV attenuation, the M2-S86A mutation was introduced into LAIVs 
encoding H3N2 (A/Victoria/361/2011) or H1N1 (A/Michigan/45/2015) surface proteins 
and assessed the viruses’ growth and replication characteristics. The results showed 
opposite effects, in which H3N2 LAIV replication increased, but H1N1 LAIV replication 
decreased. The overall replication of the H1N1 LAIV, regardless of insertion of the M2-
S86A mutation, was significantly reduced compared to H3N2 LAIV. Because the failure 
of recent H1N1 LAIVs led to it being not recommended for use in the U.S. from fall 
2016 - spring 2018, I also constructed a panel of H1N1 LAIVs encoding HAs of H1N1 
vaccine strains from 2015-2018 and am assessing their ability to replicate in hNEC 
cultures and tolerate the M2 S86A mutations. These data indicate that the surface proteins 
may contribute to the attenuation of LAIV and therefore impact virus replication and 
vaccine efficacy. 
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Chapter 1: INTRODUCTION 
INFLUENZA 
Influenza is a viral respiratory disease caused by influenza virus [1] . Influenza 
virus infects epithelial cells along the respiratory tract and has two main types of human 
concern, Type A (IAV) and Type B (IBV) [2]. Influenza virus is spread through 
inhalation by droplets made when someone coughs or sneezes or by fomites left on hard 
surfaces, ultimately ending up in the mouths or noses of nearby people [3]. IAV can be 
subtyped based on the surface proteins and categorized as either seasonal or pandemic. 
PANDEMIC INFLUENZA 
Pandemic influenza is caused by an IAV not previously seen in the human 
population [4]. The lack of preexisting immunity in the human population makes the 
magnitude of a pandemic much larger than that of seasonal influenza. Only four 
pandemics have been recorded over the last 100 years, occurring in 1918, 1957, 1968, 
and 2009. Due to the random nature of the emergence of pandemic influenza viruses, it is 
impossible to predict when the next pandemic will occur or how impactful it will be. 
EPIDEMIOLOGY 
The 1918 pandemic. Despite incredible advances made to understand the 1918 
pandemic virus, the geographic and genomic origins of the virus remain unknown [5]. 
Analysis of RNA from preserved tissue samples of 1918 influenza cases showed some 
gene segments have a suspiciously high number of silent mutations from documented 
avian strains, while others remain deeply conserved. The contributing viruses had not 




genome. In the United States, high influenza activity was first found in military camps in 
the spring of 1918, suspected to have been brought back from Europe after fighting in 
World War I [6]. In Europe, the early waves of disease were so mild, military officials 
did not take concern of it, not wanting to cause a panic. In the fall 1918, another wave of 
disease emerged out of an Army training camp outside of Boston and caused high fatality 
rates. Before the disease presented itself, soldiers were moved from Boston to 
Philadelphia and then to other bases all across the United States, spreading the deadly 
virus with them. 
The 2009 pandemic. The first two cases of the 2009 H1N1 pandemic virus were 
recorded in Southern California in April 2009 [7]. Within one week, 10 other cases had 
been confirmed, and by June 2009, laboratory-confirmed cases were documented in over 
70 countries [7]. The specific gene segments from this virus had never been previously 
reported in humans or animals, but the hemagglutinin (HA) surface protein gene was 
closely related to the HA from the 1918 H1N1 virus [8]. Upon serological analysis, data 
suggested this similarity provided older adults some cross-reactive protection against the 
virus, explaining the surprisingly low infection and death rates in the 65 and up 
population. Conversely, this left everyone under 65-years old immunologically naïve and 
highly susceptible to contracting the disease. The virus’s genome was related to North 
American and Eurasian swine H1N1 viruses, with strong evidence suggesting the virus 
mutated in Central Mexico [9]. Further analysis showed that this virus was not circulating 
in the U.S. swine population, nor did the initial cases have exposure to pigs or each other 




States to track how the virus was spreading, how it was affecting public health efforts, 
and to quickly characterize the new virus.  
PUBLIC HEALTH CONCERNS AND IMPACTS 
The 1918 Influenza pandemic was determined to be caused by an H1N1 IAV that 
came from avian origins [11]. Estimates predict that over one-third of the world’s 
population was infected with the virus, killing 50 million people worldwide [11]. This 
pandemic saw a high rate of infection and death in the 20-40 year old age category, a 
population not typically affected by influenza with such severity. 
After the 2009 H1N1 pandemic, the Centers for Disease Control and Prevention 
(CDC) reported that 60.8 million cases, 274,304 hospitalizations, and 12,469 deaths 
occurred in the United States solely from this novel H1N1 virus [11]. Working adults 
were found to have a risk of death 8-12 times greater than a typical influenza season, a 
trend also seen in the 1918 epidemic [12]. The 2009 season started earlier than normal, 
with cases of the new virus being reported in April, when typically, the season starts 
around October. The peak of hospitalizations also occurred earlier than normal in 
October into November, as opposed to January into February. 
SEASONAL INFLUENZA 
Seasonal influenza is caused by both IAV and IBV, and it typically circulates 
during the local winter months [4]. IAV viruses are subtyped based on their HA and NA 
proteins, and the current strains found in the human population are H1N1 and H3N2 
viruses [13]. IBV viruses are not subtyped like H1N1 viruses but can be broken down 
based on lineages. Circulating human IBV are from the Yamagata and Victoria lineages. 




has a wide range of hosts, allowing for more reassortment events with novel proteins. 
This gives IAV a pandemic potential. Meanwhile, IBV’s only known hosts are humans 
and seals, greatly limiting the pandemic potential. 
EPIDEMIOLOGY 
Unlike pandemic influenza virus, seasonal influenza virus cannot be traced back 
to a location or reservoir of origin. However, due to national surveillance infrastructure, 
the CDC is able to track “when and where influenza activity is occurring, influenza-
related illness, determine what influenza viruses are circulating, detect changes in 
influenza viruses, and measure the impact influenza is having on hospitalizations and 
deaths” [15]. This data is recorded by location and age. A subset of viruses is tested 
further to characterize that season’s circulating viruses, elucidate how it changed from the 
previous season, and determine how effective the approved vaccines are against it. 
Information is updated weekly to provide a working analysis of the viruses as the season 
progresses. 
Additionally, influenza-associated deaths in children under 18 years old became a 
nationally notifiable condition in 2004 [15]. A pediatric death is defined as “a death 
resulting from a clinically compatible illness that was confirmed to be influenza by an 
appropriate laboratory diagnostic test” with “no period of complete recovery between the 
illness and death” [15]. Information about demographic, underlying conditions, co-
infections, and location are also collected. 
PUBLIC HEALTH CONCERNS AND IMPACTS 
Due to the complexity of influenza surveillance, the CDC is only able to estimate 




estimating is “to inform policy and communications related to influenza” [16]. Because 
influenza is not a nationally notifiable disease for adults, up to 50% of the population 
does not seek medical care for influenza-like symptoms, and not all influenza-driven 
deaths indicate influenza as the cause of death on death certificates [16]. These factors 
lead to underestimates of burden, therefore the CDC has developed models to estimate 
the national burden each season [17]. 
Aside from mortality, public health officials are interested in the burden of 
influenza because the illness can impact school and work attendance, daily productivity, 
and military capacity. Since 2010, the CDC estimates that influenza causes between 9.3 
million and 49 million illnesses, 140,000 – 960,000 hospitalizations, and 12,000 – 79,000 
deaths each year in the United States [18]. Current estimates, which are still being 
finalized, state that 49 million people presented symptomatic illness, 960,000 people 
were hospitalized, and 79,000 people died from influenza during the 2017-2018 season 
[18]. A study using 2003 hospitalization and death data estimate that “days of 
productivity lost due to illness” was 44 million days in 2003 [19]. Economically, the total 
economic burden of the influenza season in 2003 was $87.1 billion [19]. Of that, $16.3 
billion was attributed to lost earnings due to lost productivity from illness and loss of life. 
 
INFLUENZA VIRUS GENOME, DIVERSITY, AND REPLICATION 
 VIRION STRUCTURE 
 Influenza viruses belong to the Orthomyxoviridae family and utilize an 8-
segment, single-stranded, negative sense RNA genome [14]. Specifically for IAV, the 




ion channel are seen on the outside of the viral envelope. Moving inwards, M1 surrounds 
the virion core. NS2 and the ribonucleoprotein complex is composed of RNA segments 
coated by NP and the PB1, PB2, and PA proteins, forming the heterotrimeric RNA-
dependent RNA polymerase are found internal to M1 [14]. 
 ANTIGENIC DRIFT 
 Antigenic drift is change in the virus seen due to small changes over time as the 
virus replicates [20]. Typically, changes this small result in viruses that are closely 
related to each other and usually share antigenic properties. Over time, as the viruses 
continue to replicate, enough small changes can result in a virus a larger distance away 
from its predecessor. Due to the small changes, antigenic drift happens frequently. 
Antigenic drift is most relevant to the influenza HA and NA proteins, as antibodies to 
those proteins are associated with protection from disease.  
 ANTIGENIC SHIFT 
 Antigenic shift is a major change in the genome that results in HA or NA proteins 
that have not been seen in the human population becoming dominant in human influenza 
viruses [20]. These new surface proteins typically mean that there is little to no 
preexisting antibody immunity in the human population against them, allowing the virus 
to replicate with little immunological interference and being able to spread more freely 
than its predecessor virus. This is what generates pandemic influenza viruses. Because of 




 REPLICATION CAPACITY 
 Like any virus, influenza virus goes through the basic sequence of the viral 
replication cycle [14]. Viral attachment is facilitated by influenza virus HA recognizing 
sialic acid on the host cell surface. In humans, this is predominantly α-2,6 sialic acid. 
After attachment, the virus is endocytosed and uncoated. After being uncoated, 
ribonucleoproteins are moved to the host cell nucleus. In the nucleus, the viral negative 
sense RNA is used as a template to synthesize one positive-sense mRNA strand as a 
template for viral protein synthesis and one positive-sense cRNA strand to be used to 
generate more copies of negative-sense vRNA. The mRNA generates its own poly-A tail 
from a stretch of uracil residues on the vRNA and “cap snatches” from host pre-mRNA. 
The mRNA is ready to be exported and translated further. All 8 segments must be present 
in a new virion for the new virus to be infectious. Virus budding occurs at the cell 
membrane and is facilitated by the sialidase activity of NA, which prevents virus particles 
from clumping together or reattaching to the cell the particles budded from by removing 
sialic receptors from those cells and viruses. 
 To this end, in order for a virus particle to be infectious, it must contain all 8 
genome segments. After a single round of replication across an array of IAV strains, of 
cells infected with a single virion of IAV, up to 90% released noninfectious particles 
[21]. In addition to the replication process necessary to generate infectious particles, 
defective interfering (DI) particles, noninfectious particles that carry an incomplete 




 MATRIX PROTEIN 
 As previously stated, the M genome segment encodes 2 proteins, M1 and M2[14]. 
Despite being from the same genome segment, M1 and M2 have very different roles, 
which differ between IAV and IBV. 
 M1 
The M1 protein is a 252 amino acid matrix protein that surrounds the inner 
surface of the virion membrane. It has lipid binding components and interacts with the 
cytoplasmic tails of the viral membrane proteins M2, HA and NA. M1 is the primary 
coordinator of viral budding [23]. HA has been shown to stimulate M1 binding to the 
virion membrane. M1 is able to regulate viral budding in the absence of M2 [24]. M1 can 
be associated with viral budding, regardless of whether a genome has been packaged. 
M2 
M2 proteins are 97 amino acid ion channel membrane proteins. It has been found 
that for every one M2 protein, there are anywhere from 10-100 HA proteins packaged 
into virions [14]. M2 has noted roles in viral entry, membrane scission, and infectious 
virus particle production [25]. M2 allows for the translocation of hydrogen ions into the 
virion interior and allows the vRNP dissociated from the viral membrane, facilitating 
transport to the host cell nucleus for replication [26]. Mutations in the M2 cytoplasmic 
tail, particularly changing the tyrosine at position 76, have shown decreases in virion 
infectivity, producing particles with reduced amounts of viral nucleoprotein and genomic 
RNA, and changes in virion morphology [24],[26]. When the distal tail of M2 is 
truncated, the number of infectious viral particles decreases significantly. During the cold 






 amino acid of master donor H2N2 strain. This mutation has been shown to contribute 
to the attenuation phenotype of LAIV on an H3N2 backbone and replicate lower on 
human nasal epithelial cells (hNECs) at 37°C [25]. 
 HA 
 Hemagglutinin (HA) is a glycoprotein on the influenza virus surface that is 
responsible for receptor binding and membrane fusion [27]. Conserved residues in the 
head of the HA protein bind to sialic acids on host cells surfaces [27]. After the virus is 
bound to the receptor and the pH is lowered, HA mediates fusion of the virus membrane 
to the cell’s endosomal membranes [28]. During this activation, HA undergoes a dramatic 
structural change, and where these changes occur characterize HAs into two groups [28]. 
As previously mentioned, human influenza viruses bind to α2,6-linked sialic acids, found 
predominantly in the human upper respiratory tract, while avian viruses preferentially 
bind to α2,3-linked sialic acid [28]. Swine, however, bind both kinds of sialic acid. Due 
to this, several pandemics, including the 2009 H1N1 pandemic, can be traced back to 
swine internal influenza proteins gaining human surface proteins and circulating in the 
naïve human population [29]. Mutations on HA can influence binding affinity and 
specificity by changing the sequence around the receptor-binding site, affecting the 
virus’s ability to bind. Notably, a Q223R mutation on HA has shown increased 
replication in embryonated eggs by changing the binding preference from α2,6-linked 
sialic acids to α2,3-linked sialic acids [30]. An E47K mutation on the HA2 subunit on the 
stalk of HA, found in H1N1 viruses after 2009, has been found to stabilize HA, lower the 
required pH for fusion, and raise the acidic stability [31]. This resulted in higher thermal 




to these kinds of mutations, generic antigenic drift mutations occur in HA and make 
annually updating the surface proteins of the vaccine viruses necessary. 
 
INFLUENZA VACCINE 
 A vaccine against influenza virus has been available since 1933, but that first 
vaccine only contained one strain of IAV [32]. Current vaccines contain 4 different 
viruses, an IAV H1N1, IAV H3N2, IBV from the Yamagata lineage, and an IBV from 
the Victoria lineage [33]. The most common way influenza vaccines are manufactured is 
using an egg-based process regulated by the Food and Drug Administration [34]. CDC or 
a WHO Global Influenza Surveillance and Response System laboratories provide private 
manufacturers with the vaccine viruses that have been grown in eggs. The viruses are 
injected into embryonated hen’s eggs, where they replicate. This process requires 
millions of eggs and a long time to generate the amount of virus necessary. Due to this 
lengthy process, the viruses to be used in the upcoming winter are selected in February, 
which limits the amount of research and surveillance CDC can conduct on circulating 
strains and may prevent the best virus from being selected.  
There are 2 main compositions of influenza vaccines, which are based on how the 
viruses in the vaccine are generated- inactivated influenza vaccine (IIV) and live 
attenuated influenza vaccine (LAIV) [33].  
 INACTIVATED INFLUENZA VACCINE 
 As the name indicates, the IIV contains inactivated virus. The first inactivated 
vaccine was generated in the late 1930s, with widespread generation and use for the 




protect troops going to Europe to fight in World War II. With that, the head of the U.S. 
Army Commission, Thomas Francis, decided to try vaccines generated from virus grown 
in hen’s egg allantoic fluid, following Burnet’s methods, purified, and formalin 
inactivated [32]. Using both an IAV and IBV, that vaccine displayed up to 69% efficacy. 
Since then, the bivalent vaccine has been developed into a quadrivalent vaccine and 
10,000 doses to over 100 million doses [33]. 
The vaccine contains primarily HA and NA proteins, which elicit local and 
systemic immune responses with the antibody response peaking two weeks after 
vaccination and dominated by IgG [35]. Most IIVs are unadjuvanted and are 
administered via intramuscular injection [33]. In the United States, IIVs are 
recommended annually for anyone over 6 months old [33]. IIVs display anywhere from 
10% to 60% efficacy, averaging around 41% over the last 14 years across all age ranges 
[36]. In the 2017-2018 season, adults were found to have a vaccine coverage of 37.1%, 
the lowest coverage in seven seasons [37]. The rate of vaccination increased with age, as 
26.9% of 18-49 year olds were immunized while 59.6% of adults over 65 years old were 
covered [37]. As for children, ages 6 months through 17 years old, coverage during the 
2017-2018 season was 57.9%, 1.1% lower than the previous season [38]. Unlike adults, 
vaccination coverage decreased as age increased [38]. From September 2017 through 
February 2018, approximately 155.3 million doses of vaccine were distributed in the 
United States [33]. 
 LIVE ATTENUATED INFLUENZA VACCINE 
 Similarly, as the name indicates, the live attenuated influenza vaccine (LAIV) 




prevent illness. The live viruses in the vaccine allow for replication after immunization, 
to elicit a longer, more robust immune response [39]. Influenza virus was first cold 
adapted to grow at 25°C during the 1960s [40]. The IAV strain used, A/Ann Arbor/6/60, 
is an H2N2 virus that grows at the suboptimal temperature of 25°C, is unable to replicate 
above 39°C, sheds infectious virus at low levels in human pharyngeal secretions, but does 
not transmit between humans [40]. It is worth noting, that the upper portion of the human 
respiratory tract, including the nasal passageways, is at a temperature of 32°C, while the 
core body temperature, including the lower portion of the respiratory tract, is 37°C. 
Mutations in the gene segments from the cold adaption process account for the genetic 
stability of the virus and helped designate it as the “master donor virus” (MDV) for all 
human LAIVs. However, cold adapting each season’s circulating virus would not be 
efficient, so the internal gene segments of A/Ann Arbor/6/60, which contain the genetic 
determinants controlling temperature sensitivity and attenuation, are reassorted with the 
HA and NA segments of the circulating strain to generate a 6:2 reassortant virus [40]. 
This allows for the relevant surface proteins to elicit an immune response to protect 
against the currently circulating strains, while the cold-adapted internal genes provide 
consistent machinery for replication in the nasal passageway. Around the same time, 
another H2N2 MDV was being developed in Russia, A/Leningrad/134/57 [41]. An LAIV 
prophylaxis against influenza has been used in Russia since 1987. Additionally, however, 
A/Leningrad has been under study as a potential H5N1 and H7N9 pandemic LAIVs [41]. 
The LAIV used in the U.S. is manufactured by MedImmune and marketed as 
“FluMist® Quadrivalent” [42]. The trivalent form of FluMist was first approved for use 




showed less confirmed cases of influenza and more antibody cross reactivity [44],[45]. 
The vaccine itself is administered intranasally by a prefilled, single-use sprayer [42]. This 
intranasal vaccination generates an immune response that more closely resembles a 
natural immune response when compared to an intramuscular injection [39]. The lack of 
injection is very appealing for children, however, the LAIV is only licensed for persons 
older than 2 years old. The number of children able to receive the LAIV is also limited by 
a list of contraindications, including children and adolescents receiving an aspirin- or 
salicylate-containing therapy, children between 2-4 diagnosed with asthma, any child 
who is immunocompromised, and those with a history of Guillain-Barré syndrome [42]. 
Before 2009, FluMist had superior efficacy in children, aged 6 -71 months, when 
compared to that same season’s IIV [46],[43]. FluMist and the IIV demonstrated 
statistically significant and comparable protection against medically attended influenza 
during the seasons starting in 2010, 2011, and 2012 [43]. An analysis of children 
presenting to outpatient settings with influenza like illness during the 2015-2016 
influenza season showed that 10% of the total children enrolled in the study received the 
LAIV, while 31% received the IIV, and 59% were unvaccinated [47].  
However, FluMist was pulled from the US market before the 2016 influenza 
season due to poor to nonexistent effectiveness starting in the 2013 season, which studies 
later revealed was due to a faulty H1N1 component, an HN1pdm09-like virus [48]. That 
season, the IIV displayed 60%-74% protection against an A/H1N1pdm09 virus, while 
FluMist only showed 13-17% effectiveness [43]. The surface proteins of the H1N1 
component were changed so dramatically after the 2009 pandemic, that subsequent 




virus [46]. Despite a faulty H1N1 component, the H3N2 and IBV components showed 
similar effectiveness against those strains as the IIV [46]. A similar trend was seen during 
the 2015-2016 season as well, causing the Advisory Committee on Immunization 
Practices (ACIP) to remove FluMist from U.S. markets before the 2016 season [43]. It is 
worth noting, that during this time, consistent effectiveness was seen for the LAIV 
outside the U.S. [43]. Luckily, a non-significant decrease was seen in the number of 
children vaccinated the two seasons that FluMist was off the market, when compared to 
children vaccine by both IIV and FluMist the seasons before 2013 [38]. 
However, after changing the H1N1 component and adding additional efficacy 
tests, the ACIP approved the LAIV to return to the US markets for the 2018-2019 season 
[48]. The new A/Slovenia H1N1strain has displayed increased replication in nasal 
epithelial cultures and better capability to go through multiple rounds of replication, 





 In this thesis, I have studied the role of three aspects of LAIV that are rarely 
considered during the generation of seasonal LAIV. First, is the contribution of a 
mutation at position 86 of the M2 protein to the ability of LAIVs encoding either H3N2 
or H1N1 surface proteins to replicate in a temperature dependent manner. The attenuation 
of LAIV is hypothesized to be mediated by its internal gene segments, which are 
conserved irrespective of the surface proteins on that virus. Second, the effect of specific 
surface proteins on the replication of LAIV, which is often overlooked as it is assumed 
that any HA or NA can mediate effective LAIV replication and does not contribute to 
virus attenuation. Finally, the use of human nasal epithelial cells (hNECs) as a surrogate 
system to study LAIV replication in order to test LAIV replication in an environment that 
most resembles the human upper respiratory tract. My research has shown important, 




Chapter 2: CHARACTERIZATION OF M2 MUTATED VIRUSES 
BACKGROUND 
 M2 in an integral membrane protein required for virus entry, membrane scission, 
and infectious virus particle production [25]. M2 forms disulfide-linked homo-tetramers 
with pH-gated, proton-selective ion channel activity critical for virus uncoating [25]. 
Studies show that when the M2 cytoplasmic tail is truncated by 16 amino acids, 
infectious virus particle production is decreased, but when only the last 8 amino acids are 
truncated, infectious virus particle production is not changed [49]. Similarly, when the 
last 8 amino acids (M2 82-89) were mutated to alanine residues, infectious particle 
production was unchanged. However, M2-83 and M2-86 were unaltered due to having 
alanine residues before the mutations. A86 is highly conserved across human influenza 
viruses, except for 2009 pandemic H1N1 viruses, where it is a Valine, and LAIV viruses, 
which contain a Serine [25]. This chapter focuses on experiments to determine how 
mutating the 86
th
 amino acid from the LAIV WT Ser to the pre-cold adaptation Ala 





MATERIALS AND METHODS 
PLASMIDS 
The internal plasmid of pHH21 M LAIV encodes the entire influenza H2N2 
A/Ann Arbor/6/60 M segment under control of the human RNA polymerase I promotor 
and murine RNA polymerase I terminator [50]. Mutations were introduced to the plasmid 
using the QuikChange Lightning site-directed mutagenesis (Agilent, Santa Clara, CA) 
protocol. The sequences of the forward and reverse mutagenesis primers used to 
introduce the S86A mutation are in Table 1 (M2_S86A_1 and M2_S86A_2).  
Using Dpn1 enzyme for digestion, the parental DNA was removed from the PCR 
product, and the product was transformed into competent bacterial (DH5α) cells. DNA 
from multiple bacterial clones was extracted using QIAprep Spin Miniprep Kit (Qiagen). 
Using an LAIV M segment-specific primer, H2N2 LAIV Mseq 660F (Table 1), the DNA 
was sequenced for the appropriate mutations.  
CELL LINES 
Madin Darby canine kidney (MDCK) and human embryonic kidney 293T (293T) 
cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich) 
with 10% fetal bovine serum (FBS, Gibco Life Technologies), 100U penicillin/mL with 
100μg streptomycin/mL (Quality Biological), and 2mM L-Glutamine (Gibco Life 
Technologies) at 37°C with air supplemented with 5% CO2. 
Human nasal epithelial cell (hNEC) cultures were isolated from non-diseased 
tissue after endoscopic sinus surgery for non-infection related conditions [25]. The cells 




interface (ALI) in 24-well Falcon filter inserts (0.4-μM pore; 0.33cm
2
; Becton Dickinson) 
before infection, using ALI medium as basolateral medium. 
REVERSE GENETICS 
Recombinant viruses were rescued using a 12 plasmid reverse genetics system 
[50]. All eight segments of the target virus are required, in addition to helper plasmids 
encoding viral replication machinery. 293T cells were infected with 0.5μg of pHH21 
plasmids encoding A/Ann Arbor/6/60 LAIV internal genes PB2, PB1, PA, NP, NS, and 
the WT and M2-S86A mutant M. 0.5μg of A/Michigan/45/2015 HA and NA in the 
pHH21 plasmid were added to supply the surface proteins. Additionally, 1μg of protein 
expression plasmids for A/Udorn/72 PB2, PB1, and NP plus 0.2μg PA were added as 
plasmids that would reconstitute the influenza polymerase activity. When the 8 target 
virus plasmids infect the 293T cells, their corresponding vRNA is produced but unable to 
be replicated. The polymerase-containing replication machinery in the helper plasmids 
allow the vRNA to be replicated to produce more infectious virus particles. 
TransIT-LT-1 (LT1) (Mirus, Madison, WI), a transfection reagent, was mixed 
with OptiMEM medium (Gibco, Carlsbad, CA) and incubated at room temperature for 15 
minutes at a ratio of 2uL LT1 to 1ug plasmid DNA. The 12 plasmids were added to the 
solution and incubated at room temperature for 15 minutes. Complete medium was 
removed from 293T cells in 6-well plates and replaced with 2mL OptiMEM. The LT1-
OptiMEM-plasmid solutions were then added to each well. The plates were incubated at 
32°C with 5% CO2 for 24 hours. N-acetyl trypsin (NAT) (Sigma, St. Louis, MO) was 
added to a final concentration of 10ug/ml to each well, and the plates were incubated for 
another 4 hours at 32°C with 5% CO2. 5x10
5




were added to each well, and the plate was incubated at 32°C with 5% CO2. 1mL of 
transfected cell supernatant was collected and replaced with 1mL DMEM with 4ug/ml 
NAT, 100u/ml penicillin 100ug/ml streptomycin, 2mM L-Glutamine and 0.5% bovine 
serum albumin (BSA) (Sigma) (infectious medium with NAT, IM+NAT) daily until 
obvious signs of cytopathic effect were visible. 
SEQUENCING 
After plasmid, seed stock, and working stock generation, Sanger sequencing was 
utilized to confirm the appropriate M2-86 amino acid was in each virus. The sequencing 
was done at the Synthesis & Sequencing Facility of the Johns Hopkins University 
(Baltimore, MD) using Applied Biosystems 3730xl DNA Analyzer and dye terminator 
sequencing technology. DNA plasmid concentration was found using the NanoDrop 
spectrophotometer ND-1000 (Thermo Fisher Scientific). The primer H2N2 LAIV Mseq 
660F (Table 1) was used. 
SEED STOCKS AND WORKING STOCKS 
To generate seed stocks, fully confluent 6-well plates of MDCK cells were washed 2 
times with PBS+ and then infected with 250μL of the plaque pick solution for 1 hour, 
with redistribution every 15 minutes, at 32°C with 5% CO2. After 1 hour, the infection 
media was removed and 2mL of IM+NAT (1:1000) was added. Virus supernatant was 
collected with 75% of the cells showed cytopathic effect, typically 5 days post-infection. 
The seed stocks were titrated via TCID50 assay. Working stocks were generated from 
seed stocks, in a similar fashion, except on fully confluent MDCK cells in 75cm
2
 flasks, 





Plaque assays were performed in 90-100% confluent 6-well plates of MDCK 
cells. 250μL of serial 10-fold dilutions of transfection supernatant in IM+NAT (1:1000) 
were added to each well, and incubated at 32°C, for plaque picking or plaque morphology 
studies, or 37°C, for plaque morphology only, with 5% CO2 for one hour, with gentle 
distribution of the solution every 15 minutes. Wells were then covered with 2% agarose 
combined with 2X MEM plus 1:1000 NAT. Once the agarose solidified, plates were 
incubated at 32°C, for plaque picking or plaque morphology studies, or 37°C, for plaque 
morphology only, with 5% CO2 for 5 days. After 5 days, one of two protocols was 
followed. Plaques could be picked using a 1mL blunt pipette tip, added to tubes 
containing IM, and stored at -80°C to be used to establish seed stocks of the virus colony. 
Alternatively, plates could be fixed with 4% formaldehyde in PBS overnight and stained 
with Napthol Blue Black overnight to be used to quantify plaque size and morphology. 
To quantify plaque area, images of the wells were captured using a dissecting 
microscope with an Olympus DP-70 color camera. A standard ruler image was also taken 
to set a reference. Photos were opened in ImageJ (NIH), a reference length of 1cm was 
measured via the ruler image, and borders were drawn around individual plaques using 
the Freehand selector. Measurements of the area of the plaque were calculated in ImageJ, 
and data was graphed and analyzed in GraphPad Prism 8 (GraphPad Software, San 
Diego, CA). 
TCID50 ASSAY 
Fifty percent tissue culture dose (TCID50) was determined in 96-well plates of 90-




dilutions of the viruses in IM+NAT (1:1000) were made, and 20μL of each dilution was 
added to 6 wells. The plates were incubated at 32°C with 5% CO2 for 7 days. The cells 
were fixed with 4% formaldehyde (Fisher Chemical) in PBS for at least 1 hour and then 
stained with Napthol Blue Black solution overnight. Endpoint values were calculated by 
the Reed-Muench method [51]. 
LOW MULTIPLICITY OF INFECTION (MOI) GROWTH CURVES (GC)  
Low MOI GCs were used to determine viral growth kinetics. The low MOI 
promoted multiple rounds of virus replication, thereby optimizing the detection of 
replication differences between virus strains. An MOI of 0.01 was used in MDCK cells 
and 0.1 in hNECs. For MDCK cell infections, 100% confluent 24-well plates of MDCK 
cells were washed 3 times with PBS+. The virus inoculum was diluted in IM, 100μL was 
added to the cells, and allowed to incubate at 32°C or 37°C for 1 hour, with redistribution 
every 15 minutes. The inoculum was removed, the cells were washed 3 times with PBS+ 
and incubated with 500μL of IM+NAT (1:1500). At the indicated times, all media was 
collected and fresh IM+NAT was re-supplemented. 
For hNEC cell infections, fully differentiated 24-well plates with a transwell 
membrane had their basolateral media replaced and were washed 3 times on the apical 
side with IM, with a 10 minute 32°C or 37°C with 5% CO2 incubation between each 
wash. The virus inoculum was diluted in IM, 100 μL was added to the cells, and allowed 
to incubate at 32°C or 37°C for 2 hours. The inoculum was removed, the cells washed 3 
times with PBS+ and incubated at 32°C or 37°C with 5% CO2. At the indicated times, IM 
was added to the apical side, allowed to incubate at the corresponding temperature for 10 










Rescue of recombinant influenza viruses encoding M2-S86A mutations 
 The A/Ann Arbor/6/1960 (H2N2) LAIV M2 protein contains an Alanine to Serine 
mutation at position 86 of the M2 cytoplasmic tail, which was acquired during the cold 
adaptation process of the virus [52]. Recombinant A/Michigan/45/2015 H1N1 viruses 
expressing either LAIV M2-WT or LAIV M2-S86A were successfully generated. The 
entire coding region of the M segment of each virus was sequenced to confirm the 
expression of the desired mutation and to verify no other amino acid mutations were 
present. 
Recombinant A/Victoria/361/201 H3N2 viruses expressing either LAIV M2-WT 
or LAIV M2-S86A were successfully generated previously in the lab [25]. Working 
stocks of these viruses were re-titered and had the entire coding region of the M segment 
re-sequenced to confirm the expression of the desired mutation and to verify no other 
mutations occurred during the freeze-thaw cycle since the viruses’ last use.  
Plaque assay of viruses containing WT and S86A M2 
 To determine how this mutation may affect virus replication at each temperature, 
plaque assays were performed to study plaque morphology and size on MDCK cells. 
Both H1N1 viruses were able to form plaques at both 32°C and 37°C (Fig. 1, Fig. 2). The 
area of individual plaques for each virus at each temperature was calculated. At both 
temperatures, rMich-LAIV M2-WT had significantly smaller plaques than is rMich-
LAIV M2-S86A counterpart. This result indicates that the serine mutation only seen in 




Previous rVic-LAIV M2-WT and rVic-LAIV M2-S86A plaque assays did not 
inoculate the cells at the different temperatures. The method I used would show how well 
these viruses are able to infect the cells at the temperature they would ultimately be 
incubated at as well. Both viruses were able to form plaques at both 32°C and 37°C (Fig. 
3, Fig. 4). The area of individual plaques for each virus at each temperature was 
calculated. At both temperatures, rVic-LAIV M2-WT had significantly larger plaques 
than its rMich-LAIV M2-S86A counterpart. This result indicates that the serine mutation 
only seen in the LAIV strain of H1N1 positively impacts plaque formation and cell-to-
cell spread. This is the opposite phenotype of that seen in the H1N1 rMich viruses. 
Replication of recombinant viruses at 32°C 
 To evaluate the viruses’ growth kinetics and ability to survive multiple rounds of 
replication, multistep low MOI growth curves of both viruses were performed on MDCK 
cells and differentiated hNECs at 32°C to replicate the temperature of the upper portion 
of the human respiratory tract. 
 On MDCK cells, all 4 recombinant viruses reached a peak infectious virus titer at 
48 hours post infection (Fig. 5, Fig. 6). rMich-LAIV M2-WT reached and sustained its 
highest titer faster and longer than rMich-LAIV M2-S86A, while the differences between 
the viruses was slightly less than 10-fold, the differences were statistically significant. In 
contrast, there were no statistically significant differences between rVic-LAIV M2-WT 
and rVic-LAIV M2-S86A. When the H1N1 viruses are compared to the H3N2 viruses, 
the H3N2 viruses’ peak viral titers were 1 to 1.5 logs higher than the M2-WT and M2-




M2-S86A on the replication of H1N1 LAIV but not on H3N2 LAIV at 32°C in MDCK 
cells.  
 In hNEC cultures, rMich-LAIV M2-WT reached its highest titer by 48 hours post 
infection, while rMich-LAIV M2-S86A peaked at 72 hours post infection (Fig. 7). The 
difference between the peak titers of the two viruses was 10-fold, with rMich-LAIV M2-
WT having the higher titer. Over the course of the assay, rMich-LAIV M2-WT had over 
a 10-fold higher titer than rMich-LAIV M2-S86A. In contrast, both H3N2 viruses 
reached their peak viral titers at 72 hours post infection, with rVic-LAIV M2-S86A 
reaching an ultimately higher viral titer than its counterpart, but this difference was less 
than a 10-fold difference (Fig. 8). The kinetics of these viruses was similar, with rVic-
LAIV M2-WT only reaching a higher titer at 72 hours post infection. Once again, the 
data show that M2-S86A has an effect in H1N1 LAIV but not in H3N2 LAIV, indicating 
the surface proteins can mediate a differential effect of the M2-S86A on LAIV 
replication.  
 The H3N2 viruses showed standard growth kinetics at 32°C on hNECs, with high 
amounts of infectious virus particle production between 12 and 72 hours post infection, 
while the H1N1 viruses reached significantly lower peak titers and never had a dramatic 
increase in infectious virus particle production in those first time points (Fig. 9). The 
difference in peak titers between the H3N2 viruses and the H1N1 viruses was over 1000-
fold, despite having similar inoculation titers. 
 These data show that at 32°C, the mutation does not play a significant role on 
immortalized cells for either the H1N1 or H3N2 viruses. But in a human physiologically 




while conferring not advantages for either H3N2 virus. This also started to elucidate a 
potential difference in the H1N1 viruses’ abilities to replicate on our primary cell line. 
Replication of recombinant viruses at 37°C 
 In addition to growth curves at 32°C, low MOI growth curves were performed on 
MDCK cells and in differentiated hNEC cultures at 37°C. The lower portion of the 
human respiratory tract and core human body temperature sits around 37°C, and growth 
curves at this temperature would elucidate any potential temperature sensitivity this 
mutation is responsible for.  
 On MDCK cells, both H1N1 viruses reached a peak viral titer at 48 hours post 
infection (Fig. 11). The two viruses replicated with similar kinetics and to similar titers 
over the course of the assay. The H3N2 viruses, however, reached their peak viral titer at 
36 hours post infection (Fig. 12). While they both had similar titers leading up to their 
peak titer, rVic-LAIV M2_S86A sustained a significantly higher titer level from 36 hours 
post infection on over rVic-LAIV M2-WT. However, this difference was only about half 
a log. Even though the H1N1 viruses and H3N2 viruses reached their peak titers at 
different times, they all peaked around the similar titers, with the exception of rMich-
LAIV M2-S86A, which was about 10-fold lower than either H3N2 virus (Fig. 16). 
 On hNEC cultures, rMich-LAIV M2-WT reached a peak viral titer at 36 hours 
post infection, but viral titer went below the limit of detection by 72 hours post infection. 
rMich-LAIV M2-S86A produced even less infectious virus and fell below the limit of 
detection by 24 hours post infection (Fig. 13). While the two viruses started at similar 
inoculums, their ability to replicate in hNEC cultures is drastically different. The H3N2 




both viruses at 72 hours post infection (Fig. 14). Unlike at 32°C, the difference between 
these peak titers was over 10-fold higher for rVic-LAIV M2-S86A and statistically 
significant. Throughout the most of the assay, rVic-LAIV M2-S86A had a 10-fold higher 
titer over rVic-LAIV M2-WT. This result is similar to what was previously published. 
Despite having similar inoculum titers, the H1N1 viruses are significantly worse at 
replicating on hNEC cultures at 37°C than when compared to the H3N2 viruses (Fig. 15). 
While the H1N1 viruses both fell below the limit of detection, the H3N2 viruses had not 
reached their peak titer yet. This was another indicator of these particular H1N1 surface 
proteins’ lack of capability to replicate on a physiologically relevant human model. The 
data also indicate that the effect of the M2-S86A mutation can be very different 
depending on the HA and NA proteins encoded by the LAIV.  
Replication of similar recombinant viruses at different temperatures 
As for each virus compared to its temperature different assay, on MDCK cells, 
rMich-LAIV M2-WT reached higher titers at 32°C than 37°C, which is to be expected 
due to the temperature sensitive phenotype of the LAIV virus (Fig. 5, Fig. 11). Both 
assays reached a peak titer at 48 hours post-infection and had similar decreases in 
replication after that. The same trend was found in the rMich-LAIV M2-S86A viruses, 
with peak titer being reached at 48 hours post infection and close to a 10-fold decrease in 
titer for rMich-LAIV M2-S86A viruses grown at 37°C was observed (Fig. 5, Fig. 11). 
This ensures that our temperature sensitive phenotype was held within the recombinant 
viruses. Both H3N2 viruses reached their peak viral titers at different time points at the 
same temperature on MDCKs, 48 hours post infection at 32°C and 36 hours post 




titer was seen (Fig. 6, Fig. 12). However, the difference in peak titer between the 
temperatures was less than a 10-fold difference for both viruses, suggesting that the 
surface proteins may be modulating the temperature dependent replication of LAIV. Both 
H3N2 M2-WT viruses reached a higher peak titer, about 10-fold higher, than its H1N1 
M2-WT counterpart at the same temperature (Fig. 10, Fig. 16). The same trend is seen for 
the M2-S86A viruses, with H3N2 viruses grown at either temperature reaching a higher 
titer than its H1N1 counterpart at that same temperature (Fig. 5, Fig. 6, Fig. 11, Fig. 12). 
On hNEC cultures, we see that both rMich-LAIV M2-WT and rMich-LAIV M2-
S86A viruses replicate to significantly higher titers at 32°C than at 37°C (Fig. 7, Fig. 13). 
However, both viruses had very different growth kinetics at both temperatures. rMich-
LAIV M2-WT peaked at different points during the assay between the temperatures and 
had over a 10-fold difference in peak titer. rMich-LAIV M2-S86A had over a 100-fold 
difference between peak titers, with the virus unable to replicate at 37°C. As for the 
H3N2 viruses, all the viruses reached their peak titers at the same time at both 
temperatures at 72 hours post infection. rVic-LAIV M2-WT grown at 37°C had over a 
2.5-log decrease in peak titer compared to when it was grown at 32°C (Fig. 8, Fig. 14). 
rVic-LAIV M2-S86A had a 2-log difference between the viruses grown at 32°C and 
37°C, with the viruses at 32°C reaching the higher titer. Similar to the H1N1 viruses, this 
keeps wells with the temperature sensitive phenotype seen in LAIV viruses. The peak 
titer for rVic-LAIV M2-WT at 32°C was over 1000-fold higher than the peak titer than 
rMich-LAIV M2-WT’s peak titer, and the peak titer at 37°C was over 100-fold higher for 
the H3N2 M2-WT virus than the H1N1 M2-WT (Fig. 9, Fig. 15). The peak titers for the 




infectious virus particle (Fig. 7, Fig. 8). At 37°C, the H3N2 M2-S86A virus replicated 
over 5-logs higher, but that is also due to the fact that the H1N1 M2-S86A virus did not 





























































Fig. 1- Plaque Assay at 32°C. Plaque assays performed with indicated virus at 32°C. (A) Plaque area was 
calculated and individual plaque area and mean (crossbar) are shown. Significance determined with an 
unpaired t-test, *p<0.05. At least 60 plaques were quantified per virus. (B) Plaque morphology of 















































H1N1 LAIV M2-S86A H1N1 LAIV M2-WT 
A 
B 
Fig. 2- Plaque Assay at 37°C. Plaque assays performed with indicated virus at 37°C. (A) Plaque area 
was calculated and individual plaque area and mean (crossbar) are shown. Significance determined with 
an unpaired t-test, *p<0.05. At least 60 plaques were quantified per virus. (B) Plaque morphology of 
















































H3N2 LAIV M2-S86A H3N2 LAIV M2-WT 
A 
B 
Fig. 3- Plaque Assay at 32°C. Plaque assays performed with indicated virus at 37°C. (A) Plaque area was 
calculated and individual plaque area and mean (crossbar) are shown. Significance determined with an 
unpaired t-test, *p<0.05. At least 60 plaques were quantified per virus. (B) Plaque morphology of 
















































H1N1 LAIV M2-S86A H3N2 LAIV M2-WT 
A 
B 
Fig. 4- Plaque Assay at 37°C. Plaque assays performed with indicated virus at 37°C. (A) Plaque area was 
calculated and individual plaque area and mean (crossbar) are shown. Significance determined with an 
unpaired t-test, *p<0.05. At least 60 plaques were quantified per virus. (B) Plaque morphology of 












































Fig. 5- 32°C H1N1 MDCK GC. A multi-step growth curve was performed on 
MDCK cells with the indicated H1N1 recombinant viruses at 32°C with an MOI 
0.01. Statistical significance was measured with a two-way ANOVA followed by 
Bonferroni post-test. Results are from 3 independent experiments, each with 4 
technical replicates. *p<0.05. 




























Fig. 6-32°C H3N2 MDCK GC.  A multi-step growth curve was performed on 
MDCK cells with the indicated H3N2 recombinant viruses at 32°C with an MOI 
0.01. Statistical significance was measured with a two-way ANOVA followed by 
Bonferroni post-test. Results are from 3 independent experiments, each with 4 

































Fig. 7- 32°C H1N1 hNEC GC.  A multi-step growth curve was performed on 
hNEC cells with the indicated H1N1 recombinant viruses at 32°C with an MOI 0.1. 
Statistical significance was measured with a two-way ANOVA followed by 
Bonferroni post-test. Results are from 3 independent experiments, each with 4 
technical replicates. *p<0.05. 





























Fig. 8- 32°C H3N2 hNEC GC.  A multi-step growth curve was performed on 
MDCK cells with the indicated H3N2 recombinant viruses at 32°C with an MOI 
0.1. Statistical significance was measured with a two-way ANOVA followed by 
Bonferroni post-test. Results are from 3 independent experiments, each with 4 

































Fig. 9- 32°C H1N1vH3N2 hNEC GC. A multi-step growth curve was performed 
on hNEC cells with the M2-WT H1N1 and H3N2 recombinant viruses at 32°C 
with an MOI 0.1. Statistical significance was measured with a two-way ANOVA 
followed by Bonferroni post-test. Results are from 3 independent experiments, 
each with 4 technical replicates. *p<0.05.MOI 0.01, Two-way ANOVA, n=3, 4 
tech. reps 





























Fig. 10- 32°C H1N1vH3N2 MDCK GC. A multi-step growth curve was 
performed on MDCK cells with the M2-WT H1N1 and H3N2 recombinant viruses 
at 32°C with an MOI 0.01. Statistical significance was measured with a two-way 
ANOVA followed by Bonferroni post-test. Results are from 3 independent 
experiments, each with 4 technical replicates. *p<0.05.MOI 0.01, Two-way 


































Fig. 11- 37°C H1N1 MDCK GC. A multi-step growth curve was performed on 
MDCK cells with the indicated H1N1 recombinant viruses at 37°C with an MOI 
0.01. Statistical significance was measured with a two-way ANOVA followed by 
Bonferroni post-test. Results are from 3 independent experiments, each with 4 
technical replicates. *p<0.05. 



























Fig. 12- 37°C H3N2 MDCK GC.  A multi-step growth curve was performed on 
MDCK cells with the indicated H3N2 recombinant viruses at 32°C with an MOI 
0.01. Statistical significance was measured with a two-way ANOVA followed by 
Bonferroni post-test. Results are from 3 independent experiments, each with 4 

































Fig. 13- 37°C H1N1 hNEC GC. A multi-step growth curve was performed on hNEC 
cells with the indicated H1N1 recombinant viruses at 37°C with an MOI 0.1. 
Statistical significance was measured with a two-way ANOVA followed by 
Bonferroni post-test. Results are from 3 independent experiments, each with 4 
technical replicates. *p<0.05. 





























Fig. 14- 37°C H3N2 hNEC GC. A multi-step growth curve was performed on 
hNEC cells with the indicated H3N2 recombinant viruses at 37°C with an MOI 
0.1. Statistical significance was measured with a two-way ANOVA followed by 
Bonferroni post-test. Results are from 3 independent experiments, each with 4 
































Fig. 15- 37°C H1N1vH3N2 hNEC GC.  A multi-step growth curve was 
performed on hNEC cells with the M2-WT H1N1 and H3N2 recombinant viruses 
at 37°C with an MOI 0.1. Statistical significance was measured with a two-way 
ANOVA followed by Bonferroni post-test. Results are from 3 independent 
experiments, each with 4 technical replicates. *p<0.05.MOI 0.01, Two-way 
ANOVA, n=3, 4 tech. reps 





























Fig. 16- 37°C H1N1vH3N2 MDCK GC. A multi-step growth curve was 
performed on MDCK cells with the M2-WT H1N1 and H3N2 recombinant viruses 
at 37°C with an MOI 0.01. Statistical significance was measured with a two-way 
ANOVA followed by Bonferroni post-test. Results are from 3 independent 
experiments, each with 4 technical replicates. *p<0.05.MOI 0.01, Two-way 




Chapter 3: CHARACTERIZATION OF H1 VARIANT VIRUSES 
BACKGROUND 
 HA is one of influenza virus’s two surface proteins and is responsible for receptor 
binding, typically to α2,6-linked sialic acids found predominantly in the human upper 
respiratory tract, and membrane fusion [27]. The most recent, notable HA change came 
during the 2009 H1N1 pandemic, where a swine-based HA protein garnered enough 
mutations to become pathogenic in the human population. Subsequent analysis of the 
new HA found several mutations that increase the virus’s thermal stability, lower the 
required pH for fusion, and increased the acidic stability [31]. With this global change in 
the circulating H1N1 virus, updates to seasonal vaccines were necessary to confer 
protection. FluMist used the surface protein from the virus being used in the IIV, 
A/California/7/2009. The A/Cal/7/2009 LAIV appeared effective in the low H1N1 
seasons following 2009, however, when a predominantly H1N1 season occurred in 2013, 
it revealed that the H1N1 component of FluMist was highly ineffective, while the IIV 
showed effectiveness around 60%. This led the manufacturer to change the surface 
proteins being used for the 2015-2016 season to A/Bolivia/55/2013. Despite the change, 
the H1N1 component of FluMist was still providing no protection against circulating 
H1N1 viruses. This led the ACIP to pull FluMist off the US market to prevent another 
season of poor vaccine efficacy. During its time off the market, the manufacturer has 
since changed the surface proteins to A/Slovenia/2903/2015. The new surface proteins 
have displayed increased replication in nasal epithelial cell cultures and increased 




 Given this information along with reviewing the data from our recombinant 
viruses’ inability to survive and replicate on hNEC cultures, this has led us to try different 
surface proteins, including a pre-2009 H1N1 (A/New Caledonia/20/99), the A/Bolivia 
HA which was in the vaccine when FluMist was pulled off of the market, and A/Slovenia 
that is currently in the licensed vaccine, with our M2 mutation. This panel of H1 surface 
proteins should elicit how well these recombinant viruses can replicate on a 






MATERIALS AND METHODS 
PLASMIDS 
Plasmids encoding A/Slovenia and A/Bolivia were designed based on available 
sequences, put into pHH21, and purchased through GenScript (GenScript USA Inc., 
Piscataway, NJ). A plasmid encoding a pre-2009 H1 HA, A/New Caledonia/20/99, is 
currently being generated through GenScript’s services. 
The internal plasmid of pHH21 M LAIV encodes the entire influenza H2N2 
A/Ann Arbor/6/60 M segment under control of the human RNA polymerase I promotor 
and murine RNA polymerase I terminator [50]. Mutations were introduced to the plasmid 
using the QuikChange Lightning site-directed mutagenesis (Agilent, Santa Clara, CA) 
protocol. The sequences of the forward and reverse mutagenesis primers used to 
introduce the S86A mutation are in Table 1 (M2_S86A_1 and M2_S86A_2).  
Using Dpn1 enzyme for digestion, the parental DNA was removed from the PCR 
product, and the product was transformed into competent bacterial (DH5α) cells. DNA 
from multiple bacterial clones was extracted using QIAprep Spin Miniprep Kit (Qiagen). 
Using an LAIV M segment-specific primer, H2N2 LAIV Mseq 660F (Table 1), the DNA 
was sequenced for the appropriate mutations.  
CELL LINES 
Madin Darby canine kidney (MDCK) and human embryonic kidney 293T (293T) 
cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich) 
with 10% fetal bovine serum (FBS, Gibco Life Technologies), 100U penicillin/mL with 
100μg streptomycin/mL (Quality Biological), and 2mM L-Glutamine (Gibco Life 




Human nasal epithelial cell (hNEC) cultures will be isolated from non-diseased 
tissue after endoscopic sinus surgery for non-infection related conditions [25]. The cells 
will be differentiated at an air-liquid interface (ALI) in 24-well Falcon filter inserts (0.4-
μM pore; 0.33cm
2
; Becton Dickinson) before infection, using ALI medium as basolateral 
medium. 
REVERSE GENETICS 
Recombinant viruses were rescued using a 12 plasmid reverse genetics system 
[50]. All eight segments of the target virus are required, in addition to helper plasmids 
encoding viral replication machinery. 293T cells were infected with 0.5μg of pHH21 
plasmids encoding A/Ann Arbor/6/60 LAIV internal genes PB2, PB1, PA, NP, NS, and 
the WT and M2-S86A mutant M. 0.5μg of A/Bolivia/55/2013 or A/Slovenia/2903/2015 
HA and A/Michigan/45/2015 NA in the pHH21 plasmid were added to supply the surface 
proteins Additionally, 1μg of protein expression plasmids for A/Udorn/72 PB2, PB1, and 
NP plus 0.2μg PA were added as plasmids that would reconstitute the influenza 
polymerase activity. When the 8 target virus plasmids infect the 293T cells, their 
corresponding vRNA is produced but unable to be replicated. The polymerase-containing 
replication machinery in the helper plasmids allow the vRNA to be replicated to produce 
more infectious virus particles. 
TransIT-LT-1 (LT1) (Mirus, Madison, WI), a transfection reagent, was mixed 
with OptiMEM medium (Gibco, Carlsbad, CA) and incubated at room temperature for 15 
minutes at a ratio of 2uL LT1 to 1ug plasmid DNA. The 12 plasmids were added to the 
solution and incubated at room temperature for 15 minutes. Complete medium was 




OptiMEM-plasmid solutions were then added to each well. The plates were incubated at 
32°C with 5% CO2 for 24 hours. N-acetyl trypsin (NAT) (Sigma, St. Louis, MO) was 
added to a final concentration of 10ug/ml to each well, and the plates were incubated for 
another 4 hours at 32°C with 5% CO2. 5x10
5
 MDCK cells in 100uL infection medium 
were added to each well, and the plate was incubated at 32°C with 5% CO2. 1mL of 
transfected cell supernatant was collected and replaced with 1mL DMEM with 4ug/ml 
NAT, 100u/ml penicillin 100ug/ml streptomycin, 2mM L-Glutamine and 0.5% bovine 
serum albumin (BSA) (Sigma) (infectious medium with NAT, IM+NAT) daily until 
obvious signs of cytopathic effect were visible. 
SEQUENCING 
After plasmid, seed stock, and working stock generation, Sanger sequencing was 
utilized to confirm the appropriate M2-86 amino acid  and HA was in each virus. The 
sequencing was done at the Synthesis & Sequencing Facility of the Johns Hopkins 
University (Baltimore, MD) using Applied Biosystems 3730xl DNA Analyzer and dye 
terminator sequencing technology. DNA plasmid concentration was found using the 
NanoDrop spectrophotometer ND-1000 (Thermo Fisher Scientific). The primer H2N2 
LAIV Mseq 660F (Table 1) was used to confirm the M protein sequence, while pHH21-1 
F and pHH21-2 R (Table 1: Primer Sequences) were used to confirm the HA proteins. 
SEED STOCKS AND WORKING STOCKS 
To generate seed stocks, fully confluent 6-well plates of MDCK cells were washed 2 
times with PBS+ and then infected with 250μL of the plaque pick solution for 1 hour, 
with redistribution every 15 minutes, at 32°C with 5% CO2. After 1 hour, the infection 




collected with 75% of the cells showed cytopathic effect, typically 5 days post-infection. 
The seed stocks were titrated via TCID50 assay. Working stocks were generated from 
seed stocks, in a similar fashion, except on fully confluent MDCK cells in 75cm
2
 flasks, 
and the seed stock inoculum was diluted to an MOI of 0.001 in IM. 
PLAQUE ASSAY 
Plaque assays are being performed in 90-100% confluent 6-well plates of MDCK 
cells. 250μL of serial 10-fold dilutions of transfection supernatant in IM+NAT (1:1000) 
were added to each well, and incubated at 32°C, for plaque picking or plaque morphology 
studies, or 37°C, for plaque morphology only, with 5% CO2 for one hour, with gentle 
distribution of the solution every 15 minutes. Wells were then covered with 2% agarose 
combined with 2X MEM plus 1:1000 NAT. Once the agarose solidified, plates were 
incubated at 32°C, for plaque picking or plaque morphology studies, or 37°C, for plaque 
morphology only, with 5% CO2 for 5 days. After 5 days, one of two protocols was 
followed. Plaques could be picked using a 1mL blunt pipette tip, added to tubes 
containing IM, and stored at -80°C to be used to establish seed stocks of the virus colony. 
Alternatively, plates could be fixed with 4% formaldehyde in PBS overnight and stained 
with Napthol Blue Black overnight to be used to quantify plaque size and morphology. 
To quantify plaque area, images of the wells will be captured using a dissecting 
microscope with an Olympus DP-70 color camera. A standard ruler image was also taken 
to set a reference. Photos were opened in ImageJ (NIH), a reference length of 1cm was 
measured via the ruler image, and borders were drawn around individual plaques using 




ImageJ, and data was graphed and analyzed in GraphPad Prism 8 (GraphPad Software, 
San Diego, CA). 
TCID50 ASSAY 
Fifty percent tissue culture dose (TCID50) was determined in 96-well plates of 90-
100% confluent MDCK cells. After being washed twice with PBS+, ten-fold serial 
dilutions of the viruses in IM+NAT (1:1000) were made, and 20μL of each dilution was 
added to 6 wells. The plates were incubated at 32°C with 5% CO2 for 7 days. The cells 
were fixed with 4% formaldehyde (Fisher Chemical) in PBS for at least 1 hour and then 
stained with Napthol Blue Black solution overnight. Endpoint values were calculated by 
the Reed-Muench method [51]. 
LOW MULTIPLICITY OF INFECTION (MOI) GROWTH CURVES (GC)  
Low MOI GCs are being used to determine viral growth kinetics. The low MOI 
promoted multiple rounds of virus replication, thereby optimizing the detection of 
replication differences between virus strains. An MOI of 0.01 is used in MDCK cells and 
0.1 in hNECs. For MDCK cell infections, 100% confluent 24-well plates of MDCK cells 
are washed 3 times with PBS+. The virus inoculum is diluted in IM, 100μL is added to 
the cells, and allowed to incubate at 32°C or 37°C for 1 hour, with redistribution every 15 
minutes. The inoculum is removed, the cells are washed 3 times with PBS+ and incubate 
with 500μL of IM+NAT (1:1500). At the indicated times, all media is collected and fresh 
IM+NAT was re-supplemented.  
For hNEC cell infections, fully differentiated 24-well plates with a transwell 
membrane will have their basolateral media replaced and will be washed 3 times on the 




each wash. The virus inoculum will be diluted in IM, 100 μL will be added to the cells, 
and allowed to incubate at 32°C or 37°C for 2 hours. The inoculum is removed, the cells 
are washed 3 times with PBS+ and incubate at 32°C or 37°C with 5% CO2. At the 
indicated times, IM will be added to the apical side, allowed to incubate at the 
corresponding temperature for 10 minutes, and then collected. Basolateral media will be 
collected and replaced every 48 hours. Infectious virus particle production was quantified 






Rescue of recombinant influenza viruses encoding M2-S86A mutations 
 The A/Ann Arbor/6/1960 (H2N2) LAIV M2 protein contains an Alanine to Serine 
mutation at position 86 of the M2 cytoplasmic tail, which was acquired during the cold 
adaptation process of the virus [52]. Recombinant H1N1 viruses expressing 
A/Bolivia/55/2013 and A/Slovenia/2903/2015 HA with either LAIV M2-WT or LAIV 
M2-S86A were successfully generated. The entire coding region of the M segment of 
each virus was sequenced to confirm the expression of the desired mutation and to verify 
no other amino acid mutations were present. The HA segments were also sequence 
verified. 
Replication of recombinant viruses at 32°C 
 To evaluate the viruses’ abilities to survive multiple rounds of replication and 
spread cell to cell, multistep low MOI growth curves of both viruses were performed on 
MDCK cells and differentiated hNECs at 32°C to replicate the temperature of the upper 
portion of the human respiratory tract. 
 On MDCK cells, rSlov-LAIV M2-WT and rBol-LAIV M2-S86A both reached 
peak infectious virus titer at 36 hours post infection, while rBol-LAIV M2-WT and 
rSlov-LAIV M2-WT reached it at 48 hours post infection (Fig. 17). rSlov-LAIV M2-
S86A reached the highest peak titer and rSlov-LAIV M2-WT reached the lowest highest 
titer, but this difference is less than 5-fold and not considered biologically relevant. rBol-
LAIV M2-WT took longer and lower titers leading up to reach its peak viral titer than 
rSlov-LAIV M2-WT but sustained a higher titer after 48 hours than rSlov-LAIV M2-WT, 




S86A reached a lower peak titer faster, with higher titers leading up to its peak titer, than 
rSlov-LAIV M2-S86A, but rSlov-LAIV M2-S86A sustained a higher viral titer after its 
peak titer, and these differences were found to be statistically significant. These data 
suggest that there is some biologically relevant difference between the initial kinetics 
based on the HA and M proteins used, but the ultimate viral titer is not affected by these 
proteins on immortalized cells. 
 
Replication of recombinant viruses at 37°C 
In addition to growth curves at 32°C, low MOI growth curves were performed on 
MDCK cells at 37°C. The lower portion of the human respiratory tract and core human 
body temperature sits around 37°C, and growth curves at this temperature would 
elucidate any potential temperature sensitivity this mutation is responsible for.  
On MDCK cells, all viruses except rSlov-LAIV M2-WT reached a peak viral titer 
at 48 hours post infection, while rSlov-LAIV M2-WT reached its peak titer at 24 hours 
post infection (Fig. 18). rBol-LAIV M2-WT and rSlov-LAIV M2-S86A replicated with 
similar kinetics both before and after they reached their peak viral titers and reached 
similar levels of peak titers. Meanwhile, rSlov-LAIV M2-WT and rBol-LAIV M2-S86A 
replicated with higher kinetics before reaching their peak viral titers, and rBol-LAIV M2-
S86A reached a similar peak titer as rBol-LAIV M2-WT and rSlov-LAIV M2-S86A. 
Given the up to 3-log growth difference in kinetics before and 1.5-log difference in viral 
titer after 48 hours post infection, there was a statistically significant difference between 
rSlov-LAIV M2-WT and rBol-LAIV M2-WT. Meanwhile, rBol-LAIV M2-S86A grew to 
higher titers in the first half of the assay, but rSlov-LAIV M2-S86A had a higher peak 




did not display a statistical significance. Despite occurring on immortalized cells, this 
assay could be hinting at the effect of the higher temperature on replication between these 
viruses.  
Replication of similar recombinant viruses at different temperatures 
 As for each virus compared to its temperature different assay, on MDCK cells, 
rSlov-LAIV M2-WT and rSlov-LAIV M2-S86A reached and maintained higher titers at 
32°C than 37°C, which is expected due to the temperature sensitive phenotype of the 
LAIV virus (Fig. 19). This ensures that our temperature sensitive phenotype was held 
within the recombinant viruses. rSlov-LAIV M2-WT reached peak titers at 36 hours post 
infection for both temperatures, while rSlov-LAIV M2-S86A reached peak viral titer at 
48 hours post infection at both temperatures. The difference between the peak titers for 
rSlov-LAIV M2-WT was less than 4-fold, which is quite different from the 7-fold, and 
more biologically relevant, difference of rSlov-LAIV M2-S86A. While the difference 
between the kinetics of rSlov-LAIV M2-WT and rSlov-LAIV M2-S86A at 32°C was not 
found to be statistically significant, the differences before and after peak viral titer were 
reached at 37°C was statistically significant. Given the higher peak viral titers and 
sustained titers after, at both 32°C and 37°C, rSlov-LAIV M2-S86A may be more fit than 
rSlov-LAIV M2-WT.  
 For the recombinant A/Bolivia viruses, both rBol-LAIV M2-WT and rBol-LAIV 
M2-S86A had faster kinetics and higher titers at 32°C than 37°C, which is to be expected 
(Fig. 20). A 10-fold difference was seen between each respective virus at both 
temperatures. rBol-LAIV M2-S86A was the only recombinant Bolivia virus to reach a 




post infection. Given the more than 10-fold difference between the kinetics of rBol-LAIV 
M2-WT and rBol-LAIV M2-S86A, a statistically significant difference was seen at 32°C. 
Despite the difference in the early kinetics of both viruses at 37°C, the peak titer and 
subsequent kinetics did not show a statistical significance. Unlike the recombinant 
Slovenia viruses, the differences between rBol-LAIV M2-WT and rBol-LAIV M2-S86A 









































































Fig. 17- 32°C H1 panel MDCK GC. A multi-step growth curve was performed 
on MDCK cells with the indicated H1N1 recombinant viruses at 32°C with an 
MOI 0.01. Statistical significance was measured with a two-way ANOVA 
followed by Bonferroni post-test. Results are from 2 independent experiments, 
each with 4 technical replicates. *p<0.05. 
Fig. 18- 37°C H1 panel MDCK GC. A multi-step growth curve was performed 
on MDCK cells with the indicated H1N1 recombinant viruses at 37°C with an 
MOI 0.01. Statistical significance was measured with a two-way ANOVA 
followed by Bonferroni post-test. Results are from 2 independent experiments, 





































































Fig. 20- 32°C and 37°C rSlovenia MDCK GC. A multi-step growth curve was performed on MDCK cells with the 
indicated H1N1 recombinant viruses at 32°C and 37°C with an MOI 0.01. Statistical significance was measured with a 
two-way ANOVA followed by Bonferroni post-test. Results are from 2 independent experiments, each with 4 technical 
replicates. *p<0.05. 
Fig. 19- 32°C and 37°C rBolivia MDCK GC. A multi-step growth curve was performed on MDCK cells with the 
indicated H1N1 recombinant viruses at 32°C and 37°C with an MOI 0.01. Statistical significance was measured with a 






CHARACTERIZATION OF M2 MUTATED VIRUSES 
 The cytoplasmic tail of the LAIV M protein has been mapped to have roles in 
genome packaging and virus attenuation [25]. Disruption in this tail led to a defect in 
infectious virus particle production, and specifically the amino acid in the 86
th
 position 
may have a significant role in this phenotype. After finding that the only difference 
between the WT and cold-adapted strains of the master donor virus for LAIV viruses, 
A/Ann Arbor/6/1960, was a mutation at M2 position 86, recombinant H3N2 viruses with 
both amino acids were generated. After studying the viruses’ kinetics on immortalized 
and physiologically-relevant models, the LAIV M2-WT amino acid was found to 
increase replication in hNEC cultures at 37°C, which was associated with an altered 
induction of IFN-λ production. This study aimed to characterize this mutation on an 
H1N1 backbone. Aside from further characterizing influenza virus, these results were 
relevant for LAIV virus study because FluMist was removed from the US market for the 
2016/2017 and 2017/2018 seasons due to a faulty H1N1 component. An increase in viral 
replication could show an easy mutation to introduce into the virus being used in the 
vaccine and increase vaccine efficacy. 
 However, the data presented here show that while the LAIV M2-WT amino acid 
had increased replication over the M2-S86A mutation, these differences are hard to 
interpret on hNECs since H1N1 viruses performed significantly worse than their H3N2  
counterparts, with rMich-LAIV M2-S86A failing to replicate at 37°C (Fig. 13). These 
results are also opposite of the effects seen with this mutation on an H3N2 LAIV virus. 




play no role in the virus’s ability to replicate on an immortalized cell line (Fig. 10, Fig. 
11). This phenotype has been characterize before and emphasizes the need to use 
physiologically relevant models and temperatures when working with LAIV viruses [53]. 
CHARACTERIZATION OF H1 VARIANT VIRUSES 
 The lack of studying the LAIV viruses on a human physiologically relevant cell 
culture models led to the poor selection of the H1N1 component of FluMist starting in 
2013. After several years of a decreased effectiveness and the vaccine being pulled off 
the US market, studies found that the failing H1N1 component was unable to replicate on 
human cells [46]. Previous assays to assess the candidate viruses only determined how 
well the virus was able to bind to and infect an immortalized cell line. When the new 
candidate virus was selected for the 2018/2019 season, it demonstrated the ability to not 
only to bind to and infect immortalized cells, but to infect and replicate on hNEC cultures 
as well. When the virus used in the vaccine in 2014/2015, that was ultimately removed 
from the market, was assessed under these new conditions, it was found that it failed to 
replicate on human cells, a pivotal component of a successful LAIV virus. After seeing a 
similar phenotype in the surface proteins used in our studies, we decided to test our M2-
86 mutation using the surface proteins from before the 2009 pandemic that caused the 
reformulation of FluMist, from the failed vaccine virus, and from the approved vaccine 
virus. 
 Studies using the HA protein from 2015 and 2018 are in their preliminary stages. 
Plaque assays to assess the morphology at both 32°C and 37°C are currently being 
conducted and imaged to quantify plaque size. The first replicate of a low MOI hNEC 




growth curves have been completed. Thus far, all four viruses have shown they maintain 
their temperature sensitives between 32°C and 37°C. Given the statistically significant, 
but not necessarily biologically relevant difference between rSlov-LAIV M2-WT and 
rBol-LAIV M2-WT, it is no surprise that rBol-LAIV M2-WT looked to be an effective 
vaccine virus when grown on immortalized cells. Similarly, while both M2-S86A 
mutants reach higher peak viral titers faster than their M2-WT counterpart, the true effect 
of this mutation, and the role the HA protein plays, will be more relevant when looked at 






As previously stated, the pre-2009 HA from A/New Caledonia/ 20/1999 is 
currently being generated. Upon receiving, the M2-WT and M2-S86A plasmids will be 
used to recuse the viruses and generate seed and working stocks. These new viruses, 
along with the four currently generated will be put through the “trinity” of experiments 
previously described in Chapter 2 – plaque size on MDCK cells, low MOI growth curves 
in MDCK and hNEC cultures. The rBolivia-LAIV M2-WT and M2-S86A and rSlovenia-
LAIV M2-WT and M2-S86A have working stocks which have been titered and verified, 
with early experiments underway. These experiments will demonstrate how well the 
individual viruses are able to infect neighboring cells, replicate on immortalized cells, 
and infect and replicate hNEC cultures. Once these experiments are complete, we can 
evaluate how these surface proteins factor into a virus’s ability to infect and replicate, and 
how well these different viruses can tolerate the M2-86 mutation. Ultimately, this will 
give us a glimpse into how this M2 mutation may or may not have an attenuation role. 
The use of primary epithelial cell cultures and the understanding that not all HA and NA 
proteins are created equal when it comes to replication in primary epithelial cell cultures 
has improved our understanding of how to characterize new LAIV viruses in order to 
ensure that they are replicating efficiently, and therefore have a good chance at being an 
effective influenza vaccine.  
ELISA interferon, cytokine, and chemokine panels can elucidate how the 
immunologic response is different in hNEC cultures between the viruses and how viruses 
that generate more infectious virus particles may be eliciting a different response than 




how efficient the viruses are at infected uninfected cells and if there is a difference in 
efficiency between viruses that are able to generate more infectious virus particles. These 
experiments could also provide insights into how LAIV strains may be modulating their 
replication and induced innate immune responses, perhaps also shedding light on how 




Label Purpose Sequence 
M2_S86A_1 SDM 5’- AAA ATG ACT ATC GTC AGC 
ATC CAC AGC ACT CTG CTG -3’ 
M2_S86A_2 SDM 5’- CAG CAG AGT GCT GTG GAT 




M segment sequence 
confirmation 
5’- GAC TCA TCC TAG CTC CAG 
TGC TG -3’ 
pHH21_1 HA segment sequence 
confirmation 




HA segment sequence 
confirmation 
5’- CAC TTT CGG ACA TCT GGT 
-3’ 
LAIV M 
S86V For tm 
65.9 
SDM 5’- CAA AAT GAC TAT CGT CAA 
CAT CCA CAG CAC TCT GCT 
GTT CCT -3’ 
LAIV M 
S86S Rev tm 
65.9 
SDM 5’- AGG AAC AGC AGA GTG 
CTG TGG ATG TTG ACG ATA 




New Caledonia RTPCR primer 5’- AAA GCA GGG GAA AAC 
AAA AGC AAC AAA AAA TGA 




New Caledonia RTPCR primer 5’- GAA ACA AGG GTG TTT TTC 
TCA TGA TTC TGA AAT CCT 
AAT GTC AGA TGC ATA TTC T -
3’ 
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